A phase II study comparing oral S-1 + 24-hour infusion of CPT-11 +bevacizumab with FOLFIRI+bevacizumab for metastatic colorectal cancer

A phase II study comparing oral S-1 + 24-hour infusion of CPT-11 +bevacizumab with FOLFIRI+bevacizumab for metastatic colorectal cancer - A phase II study comparing oral S-1 + 24-hour infusion of CPT-11 +bevacizumab with FOLFIRI+bevacizumab

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014664

Enrollment

100

Registered

2014-07-28

Start date

2013-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metastatic colorectal cancer

Interventions

standard therapy group (FOLFIRI+bevacizumab) trial therapy arm (Oral S-1+24-hour infusion of CPT-11+bevacizumab)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: metastatic colorectal cancer

Exclusion criteria

Exclusion criteria: performance status is 2 or 3

Design outcomes

Primary

Measure	Time frame
1 year progression-free survival	—

Secondary

Measure	Time frame
time to progression response rate overall survival adverse events	—

Countries

Japan

Contacts

Public ContactSotaro Sadahiro

Tokai Unversity Department of Gastrointestinal Surgery

sadahiro@is.icc.u-tokai.ac.jp0463-93-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026